1,769 Shares in BioNTech SE (NASDAQ:BNTX) Bought by Clear Harbor Asset Management LLC

Clear Harbor Asset Management LLC purchased a new stake in BioNTech SE (NASDAQ:BNTX) in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 1,769 shares of the company’s stock, valued at approximately $210,000.

Several other institutional investors also recently modified their holdings of BNTX. Covestor Ltd lifted its position in shares of BioNTech by 47.2% in the first quarter. Covestor Ltd now owns 415 shares of the company’s stock valued at $38,000 after buying an additional 133 shares during the last quarter. Blue Trust Inc. raised its stake in BioNTech by 491.1% in the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company’s stock valued at $55,000 after acquiring an additional 388 shares during the period. EverSource Wealth Advisors LLC lifted its holdings in BioNTech by 106.3% during the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $43,000 after purchasing an additional 252 shares during the last quarter. GAMMA Investing LLC boosted its position in BioNTech by 86.9% during the second quarter. GAMMA Investing LLC now owns 512 shares of the company’s stock worth $41,000 after purchasing an additional 238 shares during the period. Finally, Crewe Advisors LLC acquired a new position in shares of BioNTech in the first quarter valued at $75,000. 15.52% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

BNTX has been the subject of a number of research reports. Jefferies Financial Group upgraded shares of BioNTech from a “hold” rating to a “buy” rating and raised their target price for the stock from $96.00 to $150.00 in a research note on Tuesday, September 17th. Hsbc Global Res upgraded BioNTech from a “hold” rating to a “strong-buy” rating in a report on Friday, August 2nd. Deutsche Bank Aktiengesellschaft increased their target price on BioNTech from $95.00 to $150.00 and gave the stock a “buy” rating in a research note on Thursday, September 19th. HC Wainwright boosted their price target on BioNTech from $113.00 to $150.00 and gave the company a “buy” rating in a research note on Monday, October 7th. Finally, HSBC upped their price objective on BioNTech from $97.00 to $136.00 and gave the company a “buy” rating in a report on Monday, October 7th. Five research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $135.54.

BioNTech Stock Down 1.1 %

BNTX stock opened at $110.48 on Monday. BioNTech SE has a 52 week low of $76.53 and a 52 week high of $131.49. The business has a 50-day simple moving average of $107.26 and a 200 day simple moving average of $94.98. The company has a quick ratio of 7.40, a current ratio of 7.54 and a debt-to-equity ratio of 0.01. The company has a market cap of $26.26 billion, a PE ratio of 220.96 and a beta of 0.24.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, August 5th. The company reported ($3.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34). The firm had revenue of $128.70 million for the quarter, compared to the consensus estimate of $134.98 million. BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The business’s revenue was down 23.3% on a year-over-year basis. During the same period last year, the company posted ($0.86) EPS. Sell-side analysts anticipate that BioNTech SE will post -3.04 EPS for the current fiscal year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.